CDH5 and neoplasm: To assess whether the CDH5 levels detected in the patient serum samples were associated with an increased level of circulating VEGF, and potentially, therefore, tumour angiogenesis, a commercially available ELISA kit was adapted to enable measurement of 3.9–500 pg ml−1 VEGF in serum.